SI3646876T1 - Uporaba inhibitorja telomeraze imetelstat za zdravljenje mieloproliferativnih motenj in mieloproliferativnih neoplazm - Google Patents

Uporaba inhibitorja telomeraze imetelstat za zdravljenje mieloproliferativnih motenj in mieloproliferativnih neoplazm

Info

Publication number: SI3646876T1
Authority: SI; Slovenia
Prior art keywords: myeloproliferative; treatment; telomerase inhibitor; neoplasms; disorders
Prior art date: 2012-12-07

Application number

SI201332080T

Other languages

English (en)

Inventor

Monic J. Stuart

Stephen Kelsey

Original Assignee

Geron Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2013-11-15

Publication date

2024-07-31

2013-03-15 Priority claimed from US13/841,711 external-priority patent/US9375485B2/en

2013-11-15 Application filed by Geron Corporation filed Critical Geron Corporation

2024-07-31 Publication of SI3646876T1 publication Critical patent/SI3646876T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)

SI201332080T 2012-12-07 2013-11-15 Uporaba inhibitorja telomeraze imetelstat za zdravljenje mieloproliferativnih motenj in mieloproliferativnih neoplazm SI3646876T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US13/841,711 US9375485B2 (en)	2012-12-07	2013-03-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P	2013-11-05	2013-11-05
EP19187756.2A EP3646876B1 (en)	2012-12-07	2013-11-15	The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number	Publication Date
SI3646876T1 true SI3646876T1 (sl)	2024-07-31

Family

ID=50883867

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI201332080T SI3646876T1 (sl)	2012-12-07	2013-11-15	Uporaba inhibitorja telomeraze imetelstat za zdravljenje mieloproliferativnih motenj in mieloproliferativnih neoplazm
SI201331556T SI2928477T1 (sl)	2012-12-07	2013-11-15	Uporaba telomeraznega inhibitorja imetelstat za zdravljenje mielofibroze
SI201331716T SI3456333T1 (sl)	2012-12-07	2013-11-15	Uporaba telomeraznega inhibitorja imetelstat za zdravljenje mielodisplastičnega sindroma

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SI201331556T SI2928477T1 (sl)	2012-12-07	2013-11-15	Uporaba telomeraznega inhibitorja imetelstat za zdravljenje mielofibroze
SI201331716T SI3456333T1 (sl)	2012-12-07	2013-11-15	Uporaba telomeraznega inhibitorja imetelstat za zdravljenje mielodisplastičnega sindroma

Country Status (37)

Country	Link
EP (3)	EP3456333B8 (sl)
JP (6)	JP6433911B2 (sl)
KR (4)	KR20230028590A (sl)
CN (2)	CN104936602B (sl)
AP (1)	AP2015008504A0 (sl)
AU (4)	AU2013356533B2 (sl)
BR (1)	BR112015013260A2 (sl)
CA (2)	CA3188494A1 (sl)
CL (2)	CL2015001530A1 (sl)
CY (2)	CY1122169T1 (sl)
DK (3)	DK3456333T3 (sl)
EA (1)	EA032973B1 (sl)
ES (3)	ES2789176T3 (sl)
FI (2)	FI3646876T3 (sl)
FR (1)	FR25C1016I1 (sl)
HK (1)	HK1210940A1 (sl)
HR (3)	HRP20191784T1 (sl)
HU (4)	HUE045098T2 (sl)
IL (3)	IL280144B2 (sl)
LT (4)	LT3456333T (sl)
MA (2)	MA45504B1 (sl)
ME (1)	ME03538B (sl)
MX (3)	MX372753B (sl)
MY (2)	MY180634A (sl)
NL (1)	NL301326I2 (sl)
NZ (1)	NZ708920A (sl)
PH (2)	PH12019501008A1 (sl)
PL (3)	PL3646876T3 (sl)
PT (3)	PT2928477T (sl)
RS (2)	RS59363B1 (sl)
SG (3)	SG10202103341SA (sl)
SI (3)	SI3646876T1 (sl)
SM (2)	SMT201900567T1 (sl)
TN (1)	TN2015000249A1 (sl)
UA (3)	UA117116C2 (sl)
WO (1)	WO2014088785A1 (sl)
ZA (3)	ZA201504124B (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
DK3030227T3 (da)	2013-08-07	2020-04-20	Incyte Corp	Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
PT3065828T (pt)	2013-11-06	2019-04-01	Mayo Found Medical Education & Res	Métodos e materiais para tratar malignidades hematológicas
HRP20201218T1 (hr)	2015-04-23	2020-12-11	Geron Corporation	Postupci za pripremu polinukleotida uporabom pripravaka multivalentne kationske soli
EP3318276A1 (en)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CA3069010A1 (en) *	2017-07-28	2019-01-31	Geron Corporation	Methods of treating myelodysplastic syndrome
IL319432A (en) *	2018-04-30	2025-05-01	Kartos Therapeutics Inc	Methods of treating cancer
AU2019273850B2 (en)	2018-05-25	2024-11-14	Kartos Therapeutics, Inc.	Methods of treating myeloproliferative neoplasms
CA3104537A1 (en) *	2018-07-31	2020-02-06	Geron Corporation	Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
JP7650798B2 (ja)	2018-11-29	2025-03-25	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
JP7767279B2 (ja)	2019-11-04	2025-11-11	ジェロン・コーポレーション	骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) *	2020-03-25	2021-10-07	パイオニア株式会社	状況出力装置
US20220168403A1 (en) *	2020-07-17	2022-06-02	Geron Corporation	Subcutaneous telomerase inhibitor compositions and methods for using same
WO2022159760A1 (en) *	2021-01-22	2022-07-28	The Regents Of The University Of California	Methods for treating and ameliorating cancer
WO2024259369A1 (en) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
AU733610B2 (en)	1996-12-20	2001-05-17	Geron Corporation	Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
JP2007525414A (ja) *	2003-01-31	2007-09-06	ジェシーエルエスオウ	スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) *	2003-07-11	2006-03-08	暨南大学	抑制白血病细胞端粒酶活性的反义核酸及其应用
NZ545516A (en)	2003-09-09	2009-06-26	Geron Corp	Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en)	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
FR2877013A1 (fr)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1876893B1 (en)	2005-04-15	2012-04-11	Geron Corporation	Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
SI2898887T1 (sl)	2006-10-30	2019-01-31	Geron Corporation	Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
CN101220044B (zh) *	2008-01-21	2010-06-02	中国药科大学	端粒酶抑制剂及其制备方法和用途

2013
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Ceased
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/me unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en not_active Ceased
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 KR KR1020257024576A patent/KR20250114449A/ko active Pending
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 MX MX2015007169A patent/MX372753B/es active IP Right Grant
- 2013-11-15 MY MYPI2020000946A patent/MY200076A/en unknown
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/xx unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active Active
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282B1/en unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja not_active Withdrawn
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
2025
- 2025-05-05 NL NL301326C patent/NL301326I2/nl unknown
- 2025-05-06 LT LTPA2025517C patent/LTPA2025517I1/lt unknown
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/hu unknown
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/fi unknown
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/fr active Active
- 2025-05-12 JP JP2025080100A patent/JP2025109842A/ja active Pending

Also Published As

Publication number	Publication date
JP2022050537A (ja)	2022-03-30
HRP20240624T1 (hr)	2024-08-02
IL317233A (en)	2025-01-01
PL3646876T3 (pl)	2024-07-22
UA128370C2 (uk)	2024-06-26
EP3646876B1 (en)	2024-02-14
TN2015000249A1 (en)	2016-10-03
ES2982897T3 (es)	2024-10-18
KR20210107906A (ko)	2021-09-01
CN111617252A (zh)	2020-09-04
EP2928477A4 (en)	2016-09-21
WO2014088785A8 (en)	2015-07-16
LT3456333T (lt)	2020-06-25
CN104936602B (zh)	2020-07-17
KR102662590B1 (ko)	2024-05-03
KR20230028590A (ko)	2023-02-28
MA45504A1 (fr)	2020-05-29
HUE049858T2 (hu)	2020-11-30
SG10201802926XA (en)	2018-05-30
RS59363B1 (sr)	2019-11-29
EA201590878A1 (ru)	2016-04-29
PL2928477T3 (pl)	2020-03-31
ZA202212327B (en)	2025-03-26
IL280144B1 (en)	2025-01-01
CL2015001530A1 (es)	2016-03-28
HUS2500019I1 (hu)	2025-05-28
JP2025109842A (ja)	2025-07-25
HRP20200993T1 (hr)	2020-11-27
HUE045098T2 (hu)	2019-12-30
ME03538B (me)	2020-07-20
AU2013356533A1 (en)	2014-06-12
CA2892907A1 (en)	2014-06-12
HK1212226A1 (en)	2016-06-10
CY1123206T1 (el)	2021-10-29
MX2020003276A (es)	2020-07-20
WO2014088785A1 (en)	2014-06-12
ZA202108991B (en)	2023-05-31
MX372753B (es)	2020-06-26
DK3646876T3 (da)	2024-05-06
AU2020267142C1 (en)	2024-08-08
AU2024203138A1 (en)	2024-07-25
SG11201504383TA (en)	2015-07-30
MA38193B1 (fr)	2018-12-31
EP3456333B1 (en)	2020-04-01
PT2928477T (pt)	2019-10-25
JP2016504307A (ja)	2016-02-12
EP3646876A1 (en)	2020-05-06
CA2892907C (en)	2023-03-21
JP2022179684A (ja)	2022-12-02
EP3456333A1 (en)	2019-03-20
IL239266A0 (en)	2015-07-30
FIC20250019I1 (fi)	2025-05-07
EP2928477B1 (en)	2019-07-24
SI3456333T1 (sl)	2020-10-30
JP2018035196A (ja)	2018-03-08
ZA201504124B (en)	2017-05-31
FR25C1016I1 (fr)	2025-06-20
CY1122169T1 (el)	2020-11-25
NZ748134A (en)	2020-10-30
MY200076A (en)	2023-12-06
IL280144A (en)	2021-03-01
AU2018282364A1 (en)	2019-05-23
KR20150091130A (ko)	2015-08-07
KR20250114449A (ko)	2025-07-29
CA3188494A1 (en)	2014-06-12
JP6433911B2 (ja)	2018-12-05
UA126015C2 (uk)	2022-08-03
EP3456333B8 (en)	2020-05-13
ES2789176T3 (es)	2020-10-26
AP2015008504A0 (en)	2015-06-30
DK3456333T3 (da)	2020-05-18
HK1210940A1 (zh)	2016-05-13
KR102294819B1 (ko)	2021-09-01
SMT202000328T1 (it)	2020-07-08
EP2928477A1 (en)	2015-10-14
MA38193A1 (fr)	2017-12-29
LT2928477T (lt)	2019-10-10
LT3646876T (lt)	2024-05-10
NL301326I2 (nl)	2025-07-31
PL3456333T3 (pl)	2020-09-21
MY180634A (en)	2020-12-03
IL239266B (en)	2019-11-28
JP7288098B2 (ja)	2023-06-06
BR112015013260A2 (pt)	2018-02-06
EA032973B1 (ru)	2019-08-30
DK2928477T3 (da)	2019-10-07
AU2013356533B2 (en)	2018-09-27
RS60401B1 (sr)	2020-07-31
MX2015007169A (es)	2016-03-31
SI2928477T1 (sl)	2019-11-29
FI3646876T3 (fi)	2024-05-14
PH12019501008A1 (en)	2022-11-14
AU2020267142A1 (en)	2020-12-03
MX2022015437A (es)	2023-01-11
IL280144B2 (en)	2025-05-01
UA117116C2 (uk)	2018-06-25
LTPA2025517I1 (sl)	2025-05-26
MA45504B1 (fr)	2021-10-29
CN104936602A (zh)	2015-09-23
JP6998191B2 (ja)	2022-02-04
NZ708920A (en)	2020-08-28
AU2020267142B2 (en)	2024-05-16
PT3456333T (pt)	2020-06-01
PH12015501282A1 (en)	2015-08-24
HRP20191784T1 (hr)	2019-12-27
CL2017002156A1 (es)	2018-05-04
HUE066402T2 (hu)	2024-07-28
SG10202103341SA (en)	2021-05-28
PH12015501282B1 (en)	2015-08-24
JP2020041001A (ja)	2020-03-19
ES2744790T3 (es)	2020-02-26
SMT201900567T1 (it)	2019-11-13
PT3646876T (pt)	2024-05-15

Publication	Publication Date	Title
ZA202108991B (en)	2023-05-31	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL242610A0 (en)	2016-02-01	History of pyrazolopyrrolidine and their use in the treatment of diseases
PL2970101T5 (pl)	2025-12-15	Proleki fumaranów i ich zastosowanie w leczeniu różnych chorób
ZA201507155B (en)	2017-01-25	Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
LT2961410T (lt)	2020-02-10	Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus
IL232256A0 (en)	2014-06-30	Novel purine derivatives and their use in the treatment of disease
ZA201604810B (en)	2017-11-29	Surface treatment of particles and their use
PL3004108T3 (pl)	2018-03-30	Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
ZA201604860B (en)	2017-09-27	Surface treatment of particles and their use
DK2838539T3 (da)	2017-11-27	Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
PL3466425T3 (pl)	2021-04-06	Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
ZA201607980B (en)	2022-04-28	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PL3004112T3 (pl)	2018-02-28	Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PL2846791T3 (pl)	2017-07-31	HPN-100 do zastosowania do leczenia zaburzeń retencji azotu
PL2988750T5 (pl)	2025-09-22	Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
PL3047851T3 (pl)	2017-10-31	Zastosowanie odiparcilu w leczeniu mukopolisacharydozy
AP2015008849A0 (en)	2015-11-30	Pyrazolopyrrolidine derivatives and their use in the treatment of disease